Form 4: Crinetics Pharmaceuticals Executive Acquires 100,000 Stock Options

Isabel Kalofonos, Chief Commercial Officer of Crinetics Pharmaceuticals, acquired 100,000 stock options on January 10, 2025.

Summary

• Isabel Kalofonos, the Chief Commercial Officer of Crinetics Pharmaceuticals, acquired 100,000 stock options on January 10, 2025.
• The exercise price of these options is $40.59 per share.
• The options vest over time, with 25% vesting on December 16, 2025, and the remaining 75% vesting monthly over the following 36 months.
• The options expire on January 9, 2035.

Sentiment

Score: 6

Explanation: The document is a routine filing related to executive compensation. It is neither particularly positive nor negative, but indicates standard business operations.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign of confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives acquire stock options. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
• The vesting schedule of 25% initially and then monthly over 36 months is a typical vesting structure for stock options.
• The 10-year expiration period is also standard for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder sentiment by aligning executive interests with company performance.

Key Dates

Keywords

stock options, executive compensation, insider trading, Crinetics Pharmaceuticals, CRNX, Isabel Kalofonos, Chief Commercial Officer